ישראל - עברית - Ministry of Health

vetmarket ltd, israel - milbemycin oxime; praziquantel - טבליות מצופות פילם - praziquantel 125 mg; milbemycin oxime 12.5 mg

ישראל - עברית - Ministry of Health

abic marketing ltd, israel - lamivudine as anhydrous; zidovudine - טבליה - zidovudine 300 mg; lamivudine as anhydrous 150 mg - zidovudine - zidovudine - antiretroviral combination therapy for the treatment of hiv infected adults and adolescents over the age of 12 years.

ישראל - עברית - Ministry of Health

pfizer pharmaceuticals israel ltd - sirolimus - תמיסה (פומי) - sirolimus 1 mg/ml - sirolimus - sirolimus - rapamune is indicated for the prophylaxis of organ rejection in adult patients at low to moderate immunological risk receiving a renal transplant. it is recommended that rapamune be used initially in combination with cyclosporine microemulsion and corticosteroids for 2 to 3 months. rapamune may be continued as maintenance therapy with corticosteroids only if cyclosporine can be progressively discontinued.

ישראל - עברית - Ministry of Health

j-c health care ltd - emtricitabine; rilpivirine as hydrochloride; tenofovir alafenamide as fumarate - טבליות מצופות פילם - tenofovir alafenamide as fumarate 25 mg; emtricitabine 200 mg; rilpivirine as hydrochloride 25 mg - rilpivirine

ישראל - עברית - Ministry of Health

j-c health care ltd - emtricitabine; rilpivirine as hydrochloride; tenofovir alafenamide as fumarate - טבליות מצופות פילם - tenofovir alafenamide as fumarate 25 mg; emtricitabine 200 mg; rilpivirine as hydrochloride 25 mg - rilpivirine

ישראל - עברית - Ministry of Health

dover medical & scientific equipment ltd, israel - factor viii (human); von willebrand factor - אבקה וממס להכנת תמיסה להזרקה - von willebrand factor 1000 iu/vial; factor viii (human) 1000 iu/vial - coagulation factor viii

ישראל - עברית - Ministry of Health

dover medical & scientific equipment ltd, israel - factor viii (human); von willebrand factor - אבקה וממס להכנת תמיסה להזרקה - von willebrand factor 500 iu/vial; factor viii (human) 500 iu/vial - coagulation factor viii

ישראל - עברית - Ministry of Health

bristol, myers squibb (israel) limited, israel - abatacept - אבקה להכנת תמיסה מרוכזת לעירוי - abatacept 250 mg - abatacept - abatacept - orencia in combination with methotrexate is indicated for the treatment of moderate to severe active rheumatoid arthritis in adult patients who responded inadequately to previous therapy with one or more disease modifying anti rheumatic drugs (dmards) including methotrexate (mtx) or a tnf-alpha inhibitor.a reduction in the progression of joint damage and improvement of physical function have been demonstrated during combination treatment with abatacept and methotrexate.polyarticular juvenile idiopathic arthritis:orencia in combination with methotrexate is indicated for the treatment of moderate to severe active polyarticular juvenile idiopathic arthritis (jia) in paediatric patients 6 years of age and older who have had an insufficient response to other dmards including at least one tnf inhibitor. orencia has not been studied in children under 6 years old.

ישראל - עברית - Ministry of Health

bristol - myers squibb, israel - entecavir; entecavir - טבליות מצופות פילם - entecavir 0.5 mg; entecavir 0.5 mg - entecavir - entecavir - baraclude is indicated for the treatment of chronic hepatitis b virus (hbv) infection in adults with compensated liver disease and evidence of active viral replication, and persistently elevated serum alanine aminotransferase (alt) levels. this indication is based on clinical trial data in patients with hbeag positive and hbeag negative hbv infection, nucleoside naive patients and patients with lamivudine-refractory hepatitis b.decompensated liver disease.

ישראל - עברית - Ministry of Health

bristol, myers squibb (israel) limited - entecavir 1 mg - film coated tablets - entecavir - baraclude is indicated for the treatment of chronic hepatitis b virus (hbv) infection in adults with compensated liver disease and evidence of active viral replication, and persistently elevated serum alanine aminotransferase (alt) levels. this indication is based on clinical trial data in patients with hbeag positive and hbeag negative hbv infection, nucleoside naive patients and patients with lamivudine-refractory hepatitis b.decompensated liver disease.